Panel · Use case · Market Access

Payer Dossier Section Review.

LiveDocument Review

Is this clinical and economic section of our payer dossier supported and consistent with the evidence we hold?

DocumentA clinical and economic section of a payer dossier

LanesAccess, HEOR, evidence, medical

ReaderAccess and HEOR leads

Not askedA re-run model

DepthStandard, four seats

Payer Dossier Section Review is a ready-made use case for Market Access. It ships under the Document Review template.

For market access leads. You get an item-by-item ledger with verdicts and risk, the substantiation each claim needs, the required changes and what the review could not check. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Is this clinical and economic section of our payer dossier supported and consistent with the evidence we hold?

Who reviews

US dossiers follow the AMCP Format, and economic evaluations are reported to the CHEERS standard. The seats review against both.

Seat	What it reviews	What it works from
Global Market Access Director	Whether the section answers what payers ask and fits the dossier structure.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}	The AMCP Format.
HEOR Evidence Lead	Model structure, inputs and reporting of the economic evaluation.^{2Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement. BMJ, 2022;376:e067975.}	The CHEERS 2022 statement.
Global Value & Evidence Lead	Whether the clinical claims match the evidence held.	Study reports and meta-analyses.
Global Medical Affairs Director	Clinical accuracy and consistency with guidelines.	Guidelines and publications.

What the review does

Every number has a source. The ledger traces each clinical and economic figure in the section to the evidence held, and marks any that cannot be located.

Reporting standard for economics. The review checks the economic section against the reporting items in CHEERS 2022 and lists those missing.^{2Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement. BMJ, 2022;376:e067975.}

Consistency inside the dossier. Claims in the clinical section must agree with those in the economic section; mismatches are listed by location.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}

Recommended length

Standard

Four lanes bear on this document. Standard depth gives each a seat, the ledger and the substantiation table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the review makes

The review states what it assumes about the document and the material supplied, and says what each gap limits. Examples for this document:

The evidence held is complete and current.
The comparator in the section is the one payers use.
The model inputs match the study reports.

Standards, guidance and sources

Framework

AMCP Format for Formulary Submissions, version 4.1.^{1Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}
CHEERS 2022: Consolidated Health Economic Evaluation Reporting Standards.^{2Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement. BMJ, 2022;376:e067975.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any input without a source, any claim in one section the other contradicts, and any model parameter that cannot be traced.

What arrives

The document under review
Overall recommendation
The review, by seat
Item-by-item ledger
Substantiation and evidence gaps
Required changes and conditions for approval
Rebuttal round
What this review could not check

What it will not do

This is analyst judgment from AI specialists and not a regulatory, medical or legal sign-off. It cannot check original data or the approved label, and the decision stays with you.

It does not re-run the economic model.

It is analyst judgment from AI specialists and not a regulatory, medical or legal sign-off.

It does not rewrite the document. It states the change and leaves the writing to the author.

It does not check original data or the approved label held by the company. Those checks need a real reviewer.

References

[1] Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019. Scope and status as given in AMCP’s release; not read in full.
[2] Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement. BMJ, 2022;376:e067975. Known by citation and the EQUATOR listing; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.